142 related articles for article (PubMed ID: 23148638)
61. Patient derived renal cell carcinoma xenografts exhibit distinct sensitivity patterns in response to antiangiogenic therapy and constitute a suitable tool for biomarker development.
Schueler J; Klingner K; Bug D; Zoeller C; Maier A; Dong M; Willecke K; Peille AL; Steiner E; Landesfeind M; Copland JA; Siegers GM; Haferkamp A; Boehm K; Tsaur I; Schneider M
Oncotarget; 2018 Jul; 9(57):30946-30961. PubMed ID: 30123419
[TBL] [Abstract][Full Text] [Related]
62. The Potential Impact of New Drug and Therapeutic Modalities on Drug Resistance to Renal Cell Carcinoma.
Pinto PC
Anticancer Res; 2023 Mar; 43(3):983-991. PubMed ID: 36854518
[TBL] [Abstract][Full Text] [Related]
63. Targeting the tumor microenvironment: focus on angiogenesis.
Fan F; Schimming A; Jaeger D; Podar K
J Oncol; 2012; 2012():281261. PubMed ID: 21876693
[TBL] [Abstract][Full Text] [Related]
64. Aortic dissection induced by vascular endothelial growth factor inhibitors.
Dai S; Zhong Y; Cui H; Zhao J; Li S
Front Pharmacol; 2023; 14():1189910. PubMed ID: 37426822
[TBL] [Abstract][Full Text] [Related]
65. Single nucleotide polymorphisms in angiogenesis-related genes and outcomes from antiangiogenic therapies in renal cell carcinoma: really a step towards personalized oncology, or not at all?
Porta C; Cosmai L; Rizzo M; Melazzini M
Ann Transl Med; 2019 Mar; 7(Suppl 1):S15. PubMed ID: 31032296
[No Abstract] [Full Text] [Related]
66. New antiangiogenic agents for renal cell carcinoma: bevacizumab.
Bukowski RM
Curr Oncol Rep; 2004 Mar; 6(2):85-6. PubMed ID: 14751083
[No Abstract] [Full Text] [Related]
67. Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma.
Voss MH; Chen D; Marker M; Hakimi AA; Lee CH; Hsieh JJ; Knox JJ; Voi M; Motzer RJ
Br J Cancer; 2016 Mar; 114(6):642-9. PubMed ID: 26908330
[TBL] [Abstract][Full Text] [Related]
68. Benefits of pazopanib over sunitinib for renal cell carcinoma.
Granovetter M
Lancet Oncol; 2016 Mar; 17(3):e93. PubMed ID: 26853821
[No Abstract] [Full Text] [Related]
69. Prognostic tissue biomarker exploration for patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Park I; Cho YM; Lee JL; Ahn JH; Lee DH
Tumour Biol; 2016 Apr; 37(4):4919-27. PubMed ID: 26526582
[TBL] [Abstract][Full Text] [Related]
70. Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art.
Randall JM; Millard F; Kurzrock R
Cancer Metastasis Rev; 2014 Dec; 33(4):1109-24. PubMed ID: 25365943
[TBL] [Abstract][Full Text] [Related]
71. A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer.
Powles T; Kayani I; Sharpe K; Lim L; Peters J; Stewart GD; Berney D; Sahdev A; Chowdhury S; Boleti E; Shamash J; Reynolds AR; Jones R; Blank C; Haanen J; Bex A
Ann Oncol; 2013 Aug; 24(8):2098-103. PubMed ID: 23579815
[TBL] [Abstract][Full Text] [Related]
72. Influence of genetic polymorphisms in vascular endothelial-related genes on the clinical outcome of axitinib in patients with metastatic renal cell carcinoma.
Numakura K; Igarashi R; Takahashi M; Nara T; Kanda S; Saito M; Narita S; Inoue T; Niioka T; Miura M; Habuchi T
Cancer Biol Ther; 2024 Dec; 25(1):2312602. PubMed ID: 38327067
[TBL] [Abstract][Full Text] [Related]
73. Sunitinib resistance in renal cell carcinoma.
Morais C
J Kidney Cancer VHL; 2014; 1(1):1-11. PubMed ID: 28326244
[TBL] [Abstract][Full Text] [Related]
74. Deep sequencing reveals microRNAs predictive of antiangiogenic drug response.
García-Donas J; Beuselinck B; Inglada-Pérez L; Graña O; Schöffski P; Wozniak A; Bechter O; Apellániz-Ruiz M; Leandro-García LJ; Esteban E; Castellano DE; González Del Alba A; Climent MA; Hernando S; Arranz JA; Morente M; Pisano DG; Robledo M; Rodriguez-Antona C
JCI Insight; 2016 Jul; 1(10):e86051. PubMed ID: 27699216
[TBL] [Abstract][Full Text] [Related]
75. Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives.
Narayan V; Haas NB
Int J Nephrol Renovasc Dis; 2016; 9():65-72. PubMed ID: 27099525
[TBL] [Abstract][Full Text] [Related]
76. Constitutional genetic variants as predictors of antiangiogenic therapy outcome in renal cell carcinoma.
Rodríguez-Antona C; García-Donas J
Pharmacogenomics; 2012 Nov; 13(14):1621-33. PubMed ID: 23148638
[TBL] [Abstract][Full Text] [Related]
77. Targeted therapy for renal cell cancer: current perspectives.
van der Veldt AA; Haanen JB; van den Eertwegh AJ; Boven E
Discov Med; 2010 Nov; 10(54):394-405. PubMed ID: 21122471
[TBL] [Abstract][Full Text] [Related]
78. Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
Albiges L; Salem M; Rini B; Escudier B
Hematol Oncol Clin North Am; 2011 Aug; 25(4):813-33. PubMed ID: 21763969
[TBL] [Abstract][Full Text] [Related]
79. [Renal cell carcinoma].
Tomita Y
Gan To Kagaku Ryoho; 2014 Feb; 41(2):172-7. PubMed ID: 24743196
[TBL] [Abstract][Full Text] [Related]
80. Predictive factors of response to treatment in patients with metastatic renal cell carcinoma: new evidence.
Tonini G; Fratto ME; Imperatori M; Pantano F; Vincenzi B; Santini D
Expert Rev Anticancer Ther; 2011 Jun; 11(6):921-30. PubMed ID: 21707289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
